Arcturus and Vinbiocare intend to apply for EUA for the vaccine in Vietnam in December this year. Credit: torstensimon from Pixabay.

The Vietnam Ministry of Health has granted approval to Arcturus Therapeutics for commencing the Phase IIIb portion of Phase I/II/III clinical trial assessing its Covid-19 vaccine, ARCT-154, against SARS-CoV-2 delta variant and other variants of concern.

The company has started dosing the subjects in the trial, which will enrol nearly 20,000 subjects.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

They will be given either two doses of the vaccine administered at a gap of 28 days or a placebo.

The approval to progress to Phase IIIb trial comes after a review of positive safety data obtained from the initial 1,000 subjects who were part of the placebo-controlled, observer-blind Phase I/II/IIIa trial.

To date, the Phase I segment has concluded the priming vaccination series with two doses in 100 people, with 75 subjects being enrolled in the ARCT-154 group.

The Phase II and Phase IIa portions are underway, enrolling 300 and 600 subjects, respectively.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Arcturus Therapeutics president and CEO Joseph Payne said: “Initiation of dosing in the Phase IIIb portion of the study brings us one step closer to our goal of filing for EUA and making it available as quickly as possible.

“As a low dose vaccine targeting variants of concern, ARCT-154 has a differentiated profile compared to currently available vaccines and we believe that our programme has the potential to become a best-in-class option for Vietnam and many other countries around the world.”

The company, along with its manufacturing partner, Vinbiocare Biotechnology, plans to seek emergency use authorization (EUA) for the vaccine in Vietnam in December this year.

This August, Arcturus reported that Vinbiocare received approval from the Vietnam Ministry of Health to conduct Phase I/II/III trial of ARCT-154.

During the same month, Arcturus and Vinbiocare signed a collaboration agreement to build a manufacturing plant in Vietnam to produce the former’s experimental Covid-19 vaccines for supply and use in the country.